HC Wainwright Has Bullish Outlook for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities research analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Lexeo Therapeutics in a research note issued on Tuesday, October 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.21) per share for the year, up from their prior forecast of ($2.32). HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($1.42) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.04.

Several other research analysts have also recently commented on LXEO. Leerink Partners boosted their price target on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Chardan Capital boosted their price target on Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Guggenheim started coverage on Lexeo Therapeutics in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target on the stock. Oppenheimer started coverage on Lexeo Therapeutics in a research note on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.57.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $9.23 on Thursday. The stock’s 50-day moving average is $6.19 and its two-hundred day moving average is $4.53. The stock has a market cap of $498.42 million, a PE ratio of -2.83 and a beta of 1.66. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $11.72.

Insider Activity

In other news, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the transaction, the insider directly owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $117,409.02. Following the transaction, the chief executive officer directly owned 242,118 shares of the company’s stock, valued at $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,091 shares of company stock valued at $232,007. 5.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC grew its holdings in Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after buying an additional 2,342 shares in the last quarter. Bank of America Corp DE grew its holdings in Lexeo Therapeutics by 22.4% in the 2nd quarter. Bank of America Corp DE now owns 26,653 shares of the company’s stock worth $107,000 after buying an additional 4,883 shares in the last quarter. Rhumbline Advisers grew its holdings in Lexeo Therapeutics by 19.8% in the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after buying an additional 4,995 shares in the last quarter. CWM LLC grew its holdings in Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after buying an additional 6,216 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Lexeo Therapeutics by 20.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after buying an additional 8,223 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.